Previous 10 | Next 10 |
Heading into the last three months of the year, there is no shortage of quality stocks for income investors to choose from now. Three of the best ones you can buy today include Viatris (NASDAQ: VTRS) , Chevron (NYSE: CVX) , and AT&T (NYSE: T) . They all pay bette...
When you're investing to boost your Social Security income in retirement, it makes the most sense to invest in companies that are capable of performing consistently and paying out for years and years, so that you don't need to worry about managing your positions. In this vein, fast growth i...
Viatris was formed as the product of a merger between Pfizer's Upjohn legacy brands division and generics drug developer Mylan. The company has a forward P/S ratio of <1x and a forward P/E ratio of <5x, suggesting it is fundamentally undervalued. The company sold its biosimi...
Pfizer's net income was $7,864 million in Q2 2022, up 131.8% QoQ. AbbVie's net income was $924 million in Q2 2022, up 20.6% year-on-year. It is unlikely that the Inflation Reduction Act will have a strong impact on the financial position of Pfizer and AbbVie. Both companies ha...
One dividend stock picking up steam of late that investors should consider buying is Viatris (NASDAQ: VTRS) . The healthcare company recently reported earnings that were incredibly positive. Shares have been on the rise -- up 13% in just the past month, right along with the S&...
Viatris Inc. ( NASDAQ: VTRS ) reported its second-quarter results on Monday and lowered the revenue outlook for the 2022 fiscal year. Michael Goettler, CEO of Viatris, said that because of strong operational performance, he believes that Viatris can absorb the foreign exchange r...
Listen on the go! A daily podcast of Wall Street Breakfast will be available this morning on Seeking Alpha , iTunes , Stitcher and Spotify . For further details see: Wall Street Breakfast: What Moved Markets
Mittleman Investment Management, LLC (“MIM”) is an SEC-registered investment adviser that provides discretionary portfolio management to individuals and institutions. The Mittleman Global Value Equity Fund (MGVEF) declined 17.6% in Q2, vs. a decline of 7.9% in the MSCI A...
Kahn Brothers' 13F portfolio value decreased from ~$788M to ~$743M this quarter. New York Community Bancorp, Citigroup, VOXX International, and ViewRay were increased while decreasing Patterson-UTI Energy during the quarter. The portfolio continues to be very concentrated with the...
Pfizer is a high-quality, high-yielding pharmaceutical company backed up by a robust drug portfolio. We appreciate Pfizer's decision to spinoff its Upjohn generics business, which was completed back in 2020, as the deal raised billions for Pfizer and ample synergies are expected going...
News, Short Squeeze, Breakout and More Instantly...
NORTHAMPTON, MA / ACCESSWIRE / July 23, 2024 / No country can make every medicine people need, and no medicine is made in every country. If a country or region relies on supply only from within their region and they experience a crisis, there is a risk people won't get the medicines they need, w...
NORTHAMPTON, MA / ACCESSWIRE / July 18, 2024 / Viatris is a global healthcare company focused on bringing high-quality medicines to patients through a hybrid approach that bridges the traditional divide between generics and brands, combining the best of both, to more holistically address healthc...
2024-07-15 10:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...